Biogen Signs an Exclusive License Agreement with Ionis for IONIS-MAPTRx
Biogen Reports Results of Spinraza (nusinersen) in P-II NURTURE Study as a Foundation of Care in Spinal Muscular Atrophy
Shots:
- Ionis to get $45M as license fee, additional milestone up to $155M plus royalties on sales and will also be responsible for P-I trial assessing IONIS-MAPTRx in patients with mild AD. Biogen will take care of all subsequent studies plus further development, including regulatory filings, and commercialization
- In 2012, Ionis and Biogen collaborated to develop and commercialize up to three novel antisense medicines to treat neurodegenerative diseases while SPINRAZA is the first product commercialized in this agreement targeted for spinal muscular atrophy (SMA) and is also developing BIIB067
- IONIS-MAPTRx is a platform targeted to reduce production of the protein tau in the central nervous system and is currently evaluated in P-I for mild AD patients
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Signbox